DSA Results (Short-Run): Cost-Effectiveness Model for a COPD Diagnostic Test

A 40-year model-based cost-utility analysis evaluating the Biofire Film Array Respiratory Panel RP 2.1+ test for COPD patients. The dataset, authored by Raymond Oppong and last updated in April 2026, contains results indicating the test is cost-saving and more effective, with potential annual savings ranging between £118 million and £18.6 billion.

Use Cases

• Replicate the cost-effectiveness model based on the described 40-year healthcare perspective and parameters.
• Analyze the impact of antimicrobial resistance (AMR) cost penalties and savings estimates on economic evaluations.
• Validate the reported cost difference of £2762.40 and QALY gain of 0.03 between intervention arms.
• Assess the probability (70% chance) of the RP 2.1+ test being cost-effective under different model assumptions.

Strengths

• Model parameters were informed by a targeted literature review and expert opinions.
• Explicitly accounts for antimicrobial resistance (AMR) using two distinct costing approaches.
• Results include specific numerical outputs: £2762.40 cost difference, 0.03 QALY difference, and a 70% probability of cost-effectiveness.
• Dataset is openly licensed under CC-BY-4.0, facilitating reuse and sharing.

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• The 5.5 KB file size suggests a very limited scope, likely containing summary model outputs rather than raw or granular data.
• The temporal coverage of the underlying model data is not specified, only the analysis horizon.

Provenance

Source

Raymond Oppong via figshare.

Collection Method

Model-based cost-utility analysis informed by a targeted literature review and expert opinions.

Time Range

Analysis conducted over a 40-year horizon.

Freshness

Last updated 2026-04-27 17:26:52; freshness should be verified.

Geography

null